Patient reported outcomes in treatment of metastatic castration-resistant prostate cancer

This phase 2 trial was conducted across 41 urological oncology sites in 11 countries in Europe and North America. Eligible patients had metastatic castration-resistant prostate cancer and had previously received chemotherapy with docetaxel and up to one additional line of previous chemotherapy. The purpose of the study was to compare the efficacy of olaparib plus abiraterone with that of placebo plus abiraterone on health-related quality of life outcomes. One hundred forty- two patients were enrolled and randomly assigned to receive oraparib and abiraterone or placebo and abiraterone.

There was no significant difference in pain or health related quality of life when olaparib was added to abiraterone. In this trial, a statistically significant radiographic progression-free survival benefit was observed with the olaparib plus abiraterone combination. Phase 3 studies are required to validate these results.

The Lancet. 2022,Sep; https://doi.org/10.1016/S1470-2045(22)00498-3.